Table 2 Results of AMP-based RNA sequencing (ArcherDx)

From: Frequent overexpression of klotho in fusion-negative phosphaturic mesenchymal tumors with tumorigenic implications

PMT#

Groupe

Sample age (year)

Cq value

RNA reads (×103)

% RNA/total reads

Fusion junctiona

Alternative junctiona

Number of unique start sites supporting the fusion junctionb

Number of unique supporting readsb

PMT-1

A

4

29.61

921

67.4

FN1 (23)—FGFR1 (3)

FN1 (23)—FGFR1 (4)

24 (76)

118 (427)

PMT-2

A

3

28.60

929

66.5

FN1 (22)—FGFR1 (3)

FN1 (22)—FGFR1 (4)

37 (56)

218 (173)

PMT-18

A

17

33.03

145

12.9

NP

NP

 

PMT-38

A

9

31.36

1171

68.4

FN1 (23)—FGFR1 (3)

FN1 (23)—FGFR1 (4)

29 (78)

215 (730)

PMT-41

A

7

31.54

893

61.0

FN1 (16)—FGFR1 (4)

NP

63

195

PMT-63

A

1

26.11

965

74.2

FN1 (24)—FGFR1 (3)

FN1 (24)—FGFR1 (4)

333 (355)

3938 (1673)

PMT-64

A

0

26.04

923

73.5

FN1 (23)—FGFR1 (9)

FN1 (23)—FGFR1 (9)c

128 (10)

1070 (11)

PMT-31

B

11

34.56

347

37.9

FN1 (23)—FGF1 (2)

NP

9

71

PMT-50

B

1

28.51

1036

71.6

FN1 (24)—FGF1 (2)

FN1 (24)—FGF1 (2)

120 (78)

1001 (281)

PMT-10

A > C

3

27.40

969

66.6

NP

NP

PMT-13

C

9

31.19

738

60.0

NP

NP

PMT-34

C

6

30.13

867

74.1

NP

NP

PMT-44

C

7

31.17

685

61.3

NP

NP

PMT-52

C

3

28.74

979

75.1

NP

NP

PMT-61

C

2

26.82

935

77.6

NP

NP

PMT-25

D

1

NP

559

33.5

NP

NP

PMT-26

D > B

7

33.09

623

56.4

FN1 (26)—FGF1 (2)

NP

7

16

PMT-27

D

6

NP

24

2.8

THRB (11)d—FGF10 (1)

NP

4

18

PMT-28

D

19

NP

4

69.2

NP

NP

PMT-46

D

8

NP

451

64.4

NP

NP

PMT-48

D

7

NP

353

37.5

NP

NP

PMT-51

D

7

33.73

595

56.6

NP

NP

PMT-58

D > C

4

31.14

807

74.9

NP

NP

  1. NP not present/performed
  2. aNumbers in parentheses indicate exons flanking the fusion junctions, and alternative junctions indicate shorter fusion products
  3. bNumbers in parentheses indicate alternative junctions
  4. c67 bp into FGFR1 exon 9, immediately 3′ to an "AG" sequence
  5. d3′ UTR
  6. ePMT-10, PMT-26, and PMT-58 were reclassified as Group C, B, and C because of revised FISH results, identification of FN1-FGF1 fusion by AMP-seq, and a metastatic hepatic tumor (PMT-58-2) later confirmed to be fusion-negative by FISH, respectively